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Stem cell therapy has been suggested to be a promising option for regeneration of injured
myocardium, for example following a myocardial infarction. For clinical use cell-based
therapies have to be safe and applicable and are aimed to renovate the architecture
of the heart. Yet for functional and coordinated activity synchronized with the host
myocardium stem cells have to be capable of forming electrical connections with resident
cardiomyocytes. In this paper we discuss whether stem cells are capable of establishing
functional electrotonic connections with cardiomyocytes and whether these may generate
a risk for arrhythmias. Application of stem cells in the clinical setting with outcomes
concerning arrhythmogenic safety and future perspectives will also briefly be touched
upon.
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INTRODUCTION
Electrical remodeling and loss of working myocardium after a
myocardial infarction (MI) remains a major health challenge
(McMurray and Pfeffer, 2005). Both processes disrupt the coor-
dinated activation and repolarization of the heart. A theoretical
remedy would be to replace the injured tissue with new car-
diomyocytes (CM) that are capable of integrating and forming
a functional network with the resident cardiomyocytes.
Stem cells have an unlimited proliferation ability and are
capable of differentiating into multiple cell types (Wagers and
Weissman, 2004). These two properties explain why so much
time and energy has been put in making cell therapy effective
for regeneration of the myocardium. Yet for proper functional
integration within the host’s myocardium there are several pre-
requisites including safety (the absence of adverse effects), a
suitable delivery mode and proper timing of delivery. Although
many questions concerning stem cells and their mechanism of
actions remain, numerous clinical trials have been performed,
with varying results.
The Myoblast Autologous Grafting in Ischemic
Cardiomyopathy (MAGIC) trial, a multicenter randomized
double blind and placebo-controlled study, was the first human
trial concerning regenerative stem cell therapy involving skeletal
myoblasts. Patients (n = 90) with prior MI, left ventricular
dysfunction [left ventricular ejection fraction (LVEF) < 35%]
and indications for coronary surgery received intra-myocardial
injections of autologous myoblasts (low dose: 4 × 108 or high
dose: 8 × 108) or placebo solutions. No changes were seen
at 6 months in either global or regional left ventricular (LV)
function between placebo treated patients and those treated
with autologous skeletal myoblast (Eisen, 2008; Menasche et al.,
2008). Arrhythmias were documented throughout the 6 months,
although there was a higher occurrence in the pooled treatment
group this was not significantly different from the control group,
most likely owing to the small number of subjects.
In the CADUCEUS trial, cardio-sphere derived stem cells
(CDC) were used, which were infused (low dose: 12.5 × 106 or
high dose: 25 × 106) into the coronary artery of patients with LV
dysfunction at 1.5–3 months post MI. The study was designed
to assess safety. At 6 and 12 months follow-up period, despite
the reduction in scar size and increase in viable myocardium
in the group receiving CDC, no differences in ejection fraction
were seen between the control and intervention groups (Makkar
et al., 2012; Pompilio et al., 2012). Similar to the MAGIC trial
non-sustained ventricular tachycardia (VT) occurred numerically
more often in the CDC treated group. However, this was not sta-
tistically significant, again due to the small number of patients (17
patients in CDC group, 8 control patients).
The investigators of the SCIPIO and BOOST trials used C-kit+
cardiac derived stem cells and autologous bonemarrow stem cells,
respectively, and did show functional improvements (Wollert
et al., 2004; Bolli et al., 2011). The SCIPIO trial enrolled and
randomized post MI patients with left ventricular dysfunction
(LVEF ≤ 40%) before coronary artery bypass surgery into either
the treatment (16 patients) or control group (7 patients) (Bolli
et al., 2011). At 4 months post-surgery 16 patients received intra-
coronary infusion of stem cells (1 × 106). At 6 months post
infusion, global improvement in left ventricular ejection frac-
tion (LVEF) by approximately 8.2 ± 2.0 LVEF units was seen.
LVEF increased by 12.3 ± 2.0 LVEF units at 1 year post treatment
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(Bolli et al., 2011). In the BOOST trial, patients who had under-
gone successful percutaneous coronary intervention for (acute)
ST-segment elevation MI were randomly assigned to the intra-
coronary bone-marrow transfer (30 patients) or to the control
infusion (30 control patients). Patients showed increased global
LVEF (about 6%) at 6 months post intracoronary infusion, which
is similar to the SCIPIO trial. The effects observed in the BOOST
trial, however, were not long-lasting and at 18 months and 5 years
follow-up no difference was detected between the cell treated and
non-cell treated groups. At 12 months post treatment the posi-
tive hemodynamic effects of the SCIPIO trial were maintained.
However, that was the last follow-up point and hence it remains
unknown whether the positive effects are long lasting or are only
maintained up to 12 months post treatment as was seen in the
BOOST trial. The SCIPIO trial investigators reported no occur-
rence of adverse arrhythmogenic events due to cell therapy such
as (ventricular) arrhythmias but did not provide a definition of
ventricular arrhythmias (Chugh et al., 2012). The BOOST trial
reported that there was no difference in occurrence of adverse
event, including arrhythmias, between treatment group and con-
trol group. However, also in this trial report, arrhythmias were not
defined (e.g., duration of VT) and only mentioned as occurrence
of VT (Meyer et al., 2006). In addition, similar to the MAGIC and
CADUCEUS trial a limited number of patients were involved.
The clinical trials show that delivery of stem cells (either by
intracoronary or intra-myocardial injection) is feasible and safe.
However, whether the applied stem cells did differentiate and con-
tribute to long-term functional improvements and safety remains
questionable. The main reasons for this uncertainty are method-
ological differences between the trials and the low number of
patients involved. Moreover, electrophysiological safety has not
been extensively addressed and the electrophysiological variables
investigated vary per study. This makes comparison between the
studies difficult (Bursac et al., 2010).
Recently two meta-analyzes on stem cell based therapies in (i)
chronic ischemic heart disease and congestive heart failure (Fisher
et al., 2014) and (ii) acute MI (de Jong et al., 2014) were pub-
lished. Each study included more than 20 randomized clinical
trials adding up to more than 1200 patients. In the first meta-
analysis concerning heart failure patients (without MI) there is
moderate evidence that stem cells improve LVEF and that it has
potential beneficial clinical outcome in terms of performance sta-
tus (at least 1 year) andmortality (Fisher et al., 2014). The authors
do underline the fact that the conclusions are still of low quality
as the studies used are small and aimed at safety and feasibil-
ity. The second meta-analysis involving cell based therapies in
patients with acuteMI noted that there was a reasonable improve-
ment in LVEF, which were explained by reduction in scar size
and sustained LV end systole volume. Unlike the meta-analysis on
heart failure no effects on clinical outcomes were found (de Jong
et al., 2014). Similar to the other meta-analysis is that the studies
included were only targeted at feasibility and safety.
Not only must cell therapy be delivered in a safe manner and
at the right time, the cells should also be capable of making elec-
trotonic connections with CM so that they can integrate and be
properly functional within the host’s myocardium. Currently, a
number of different stem cell types are known, and although
these are believed to behave differently from each other, this
paper will evaluate studies that have used cardiomyocytes and
stem cells, without focusing on one specific type/regardless of the
type. The following questions will be addressed: (i) Are stem cells
capable of forming functional intercellular connections with car-
diomyocytes? and (ii) can pro-arrhythmic effects results from the
interaction between stem cells and cardiomyocytes?
INTERCELLULAR CONNECTIONS
Gap junctions are specialized intercellular channels found in the
membranes of neighboring cardiomyocytes, and allow exchange
of ions and small molecules between cells (Kanno and Saffitz,
2001). These specialized regions are composed of two hexameric
hemichannels, one in each neighboring CM. Each hemichan-
nel, or connexon, in turn consists of 6 subunits called connexins
(Kanno and Saffitz, 2001; Dhein, 2004). The gap junctional chan-
nels allow propagation of the action potential from one cell to the
next. In normal healthy cardiomyocytes gap junctions are pre-
dominantly found at the intercalated disks, allowing the action
potential to spread predominantly along the fiber’s axis, resulting
in faster conduction along the fiber than across the fiber direction
(anisotropy) (Kanno and Saffitz, 2001).
The properties of these gap junctions play an important role in
the determination of conduction velocity, and the electrical acti-
vation of the heart. Several cardiac connexin isoforms have been
identified, each with a different channel conductance; the most
predominantly expressed gap junction in ventricular myocytes is
connexin43 (Cx43) (van Kempen et al., 1995). The lack of or loss
of Cx43 is associated with diminished electrical coupling and for-
mation of arrhythmias (de Groot et al., 2003; de Diego et al., 2008;
Procida et al., 2009). Heart failure models show that decreased
Cx43 coupling leads to an increase in conduction heterogeneity
and to an increase in the inducibility of arrhythmias (Wiegerinck
et al., 2008). The relation between uncoupling and conduction
velocity is non-linear implying that a relatively large degree of
loss of gap junctions is required to cause conduction slowing
(Jongsma and Wilders, 2000). Furthermore, reduced intercellu-
lar coupling causes increased heterogeneity of repolarization and
can contribute to a pro-arrhythmic substrate (Wiegerinck et al.,
2008).
Because gap junctions are of crucial importance for the elec-
trical activation and repolarization of the heart, alteration in gap
junctions can lead to fundamental changes in the electrical activ-
ity of the heart. Stem cells must therefore be not only capable of
coupling with CM but also do this with a sufficiently high gap
junctional conductance.
ELECTROTONIC INTERACTIONS BETWEEN STEM CELLS
AND CARDIOMYOCYTES
IN VITRO STUDIES
Various in vitro studies employing immunofluorescence staining
have shown that gap junctions containing Cx43 exist between
mesenchymal stem cells (MSC) and neonatal rat cardiomyocytes
(NRCM) (Beeres et al., 2005; Chang et al., 2006; Pijnappels et al.,
2006). Beeres et al. and Chang et al. additionally have proved,
through the use of dye transfer, that these gap junctions were
functional (Beeres et al., 2005; Chang et al., 2006).
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The question therefore remains whether the gap junctions
between MSC and cardiomyocytes also have (adverse) elec-
trophysiological consequences. Electrophysiological functionality
can be confirmed in in vitro studies with uncoupling substances
such as gap junction blockers. Intercellular uncoupling or block-
ing of the formation of electrotonic connections can be used to
detect both potential pro-arrhythmic as anti- arrhythmic con-
sequences of the interconnections between the cell types. Using
Tetrodotoxin in an in vitro co-culture of NRCM and humanMSC,
Askar et al. demonstrated that hetero-cellular coupling was the
predominant mechanism for the observed conduction slowing in
these preparations (Askar et al., 2013). Beeres et al. showed that
electrotonic coupling with human MSC was needed to join two
asynchronously beating fields of cardiomyocytes (Beeres et al.,
2005). When carbenoxolene, a potent gap junctional uncoupling
agent (de Groot et al., 2003), was added to these cultures the syn-
chronized beating of the two fields was lost (Beeres et al., 2005;
Pijnappels et al., 2006).
Another approach to establish functionality of connections
between CM and stem cells is via genetic modification. In the
in vitro model used by Beeres and Pijnappels, Cx43 knockdown
in human MSC led to failure of synchronization of two asyn-
chronously beating cardiomyocyte fields (Pijnappels et al., 2006).
Co-cultures of skeletal myoblasts and NRCM demonstrated a
decrease in conduction velocity and easily inducible re-entry,
both of which could be attenuated when skeletal myoblasts were
modified to overexpress Cx43 (Abraham et al., 2005; Tolmachov
et al., 2006; Roell et al., 2007). More efficient coupling there-
fore appears to be beneficial whereas incomplete coupling is
potentially arrhythmogenic.
IN VIVO STUDIES
Demonstrating functional coupling between stem cells and res-
ident cardiomyocytes in in vivo studies is challenging. The
implanted cells are usually not directly accessible and the lack of
high-resolution functional measurements in a beating heart ham-
pers direct assessment of functional coupling between stem cells
and endogenous cardiomyocytes. Post mortem histological analy-
ses may demonstrate successful engraftment of stem cells but not
functional coupling.
Autologous stem cells engraftment has also been established in
various studies through labeling stem cells with a cross-linkable
membrane dye (Dye IL) (Price et al., 2006), transfection with
GFP labeled lenti-virus (Valina et al., 2007; Mazo et al., 2011),
or transfected E. Coli lac Z encoding B-gal (Rigol et al., 2010).
Species-specific antibodies can determine the engraftment when
xenografted cells are applied (Chong et al., 2014). However, in
histological sections the electrophysiological interaction due to
functional gap junctions cannot be demonstrated.
Alternative techniques to establish functional coupling in vivo
is through calcium transients. Rubart et al. transplanted GFP
expressing fetal cardiomyocytes into adult mice hearts (Rubart
et al., 2003). Imaging of calcium transients in the intact heart
of both host and donor cells showed that they were identical,
encouraging the concept that cells can functionally couple to host
cells (Rubart et al., 2003). Recently, this same concept was used
to confirm functional coupling of human embryonic stem cell
derived cardiomyocytes in a non-human primate myocardium
(Chong et al., 2014). This last study convincingly supported the
idea that stem cells can form a functional and synchronized
network with the host myocardium. It has to be noted though
that the cells used in this study are cardiomyocytes created from
embryonic stem cells. This is where stem cell derived cardiomy-
ocytes are purified and cryopreserved before application.
Kehat et al. performed in vitro electrophysiological analysis of
hES that had formed spontaneous beating embryoid bodies. He
demonstrated that hES had both structural and electrical fea-
tures that resembled those of CM (Kehat et al., 2001). These
hES were not grown together with myocytes and therefore it
is not possible to state whether electrical coupling would form.
Nevertheless, the fact that these cells obtained structural fea-
tures specific for cardiomyocytes is attractive, because for proper
integration within the myocardium the current generated in the
host cell must not only pass through gap junctions to depolarize
the transplanted cell, these cells must also have the appropriate
excitation-contraction coupling properties.
PRO-ARRHYTHMIC EFFECTS OF ELECTROTONIC
CONNECTIONS
Although engraftment of stem cells may occur, it does not imply
that the engrafted cells are functionally and electrically coupled
to resident cardiomyocytes. In addition, if these cells do cou-
ple electrically it is not self-evident that these interactions can
contribute to the synchronized network of endogenous cardiomy-
ocytes without any risks or side effects. It has been suggested
that stem cells are capable of influencing the electrophysiologi-
cal properties of cardiomyocytes, resulting in the formation of
a pro-arrhythmic substrate (Chang et al., 2006; Askar et al.,
2013). Proposed mechanisms including depolarization, anatom-
ical block, abnormal automaticity and triggered activity are dis-
cussed and are schematically shown in Figure 1.
DEPOLARIZATION AND REFRACTORY PERIOD
The membrane potential of MSC has been shown to be
around −35mV (Heubach et al., 2004; Valiunas et al., 2004;
Sundelacruz et al., 2008). After electrical coupling, depolariza-
tion of the resting membrane of CM is anticipated (Xie et al.,
2009). The magnitude of depolarization depends on the mem-
brane potential of the connected stem cell, but also to the extent
of the intercellular coupling between the two cells (the cou-
pling resistance) and the size of the cells (Tan and Joyner, 1990;
Henriquez et al., 2001).
If depolarization of the resting membrane is severe (by more
than 30mV) the excitability of the cells is reduced; the voltage
gated sodium channels are inactivated, resulting in reduction in
upstroke velocity and conduction velocity (Shaw and Rudy, 1997;
Kléber and Rudy, 2004; Hubbard et al., 2007). Also, the plateau
phase is expected to be shorter while the action potential duration
is expected to be prolonged Figure 1A. Action potential prolon-
gation can lead to (unidirectional) block at tissue level and may
facilitate re-entrant arrhythmias (de Bakker et al., 1993; Coronel
et al., 2013).
Electrotonic connections between stem cells and
cardiomyocytes can also lead to the “current sink” or “current
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FIGURE 1 | Possible mechanisms of stem cell induced arrhythmias.
(A) Depolarization of cardiomyocytes reduces the upstroke velocity and
conduction velocity. (B) Clusters of stem cells can create an anatomical block
and force the electrical pathway to find a different (and longer) route.
(C) Stem cells can be spontaneously beating and may compete with the
hosts own automaticity when engrafted. Stem cells may also be capable of
inducing arrhythmias via triggered activity (D). (E) Increased sympathetic
innervation induced by stem cells can give an unbalance in the sympathetic
and parasympathetic equilibrium. (F) Paracrine factors released by stem cells
may effect electrophysiology of cardiomyocytes.
source” phenomenon (Rohr, 2004). This occurs when the load
of an excited region supplying the depolarization current is not
matched to the amount of current needed to excite the region
ahead; current to load mismatch (Rohr, 2004). Stem cells depo-
larize cardiomyocytes, suggesting that the regions where stem
cells are applied are more depolarized and that the depolarizing
current coming from these hetero-cellular areas is not enough
to excite the regions, consisting of endogenous cardiomyocytes,
around it.
Depolarization of cardiomyocytes can thus lead to a reduction
in upstroke velocity and conduction velocity but also affect the
duration and shape of an action potential. These properties are all
related to refractoriness and restitution properties (Hondeghem
et al., 2001). Alterations in restitution properties and the effective
refractory period (ERP) may lead to arrhythmias (Qu et al., 1999;
Tran et al., 2007). The ERP plays an important role, together with
conduction slowing and unidirectional block, in facilitating re-
entry arrhythmias at a multicellular level. In a porcine MI model
administration of MSC shortened ERP and resulted in steeper
ERP restitution curves (Price et al., 2006), both indicators of
electrical instability.
ANATOMICAL BLOCK
Cells used for cell-based regenerative therapies do not necessar-
ily have to couple functionally to generate potential threatening
situations for the formations of arrhythmias. Cells injected into
the myocardium can integrate in such a way that they nestle
themselves between CM causing resident CM to uncouple or
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prevent the coupling of CM (Duffy, 2008). Islands of uncou-
pled cells can cause anatomical block, forcing the electrical
wave front to find an alternative route, resulting in a possible
increased activation time over a specific region (de Bakker et al.,
1993) (Figure 2A). If this results in heterogeneous conduction
slowing it could facilitate unidirectional block and re-entrant
arrhythmias (Lammers et al., 1990; de Bakker et al., 1993).
In infarcted rat myocardium the transplanted myoblasts were
functionally isolated from the resident cardiomyocytes (Leobon
et al., 2003). Although intracellular recordings in the heart were
obtained and the action potentials evoked in the myotubes
were accompanied by (local) contractions, these did not spread
out over the myocardium (Leobon et al., 2003). Information
on conduction heterogeneity and local (fractionated) electro-
grams were not present in this publication. Both factors could
have indicated discontinuous conduction (de Bakker et al.,
1993; de Bakker and Wittkampf, 2010) a potential indicator for
arrhythmogenesis.
ABNORMAL AUTOMATICITY
Abnormal automaticity is yet another mechanism that can evoke
arrhythmias. The normal regular spontaneous sinus rhythm
can be lost because other excitable cells have a higher spon-
taneous activity than the original endogenous pacemaker cells
(Figure 1C). This could hold true for human embryonic stem
cells that form embryoid bodies of spontaneously beating car-
diomyocytes. Kehat et al. transplanted clusters of spontaneously
beating cardiomyocytes (derived from hES) into a swine with
complete atrio-ventricular block (Kehat et al., 2004). They
demonstrated that the ventricular ectopic rhythm that followed
the transplantation was localized at the site of cell transplanta-
tion. The observation that the transplanted cells were able to pace
the entire heart at first glance appears to be positive, especially for
bio-pacemaking purposes (Rosen et al., 2007; Li, 2012). However,
the pacing rhythm of the transplanted cells may interfere with the
animal’s own sinus rhythm. In a recent paper published by Chong
et al. human embryonic stem cell derived cardiomyocytes were
injected into a non-human primatemodel ofmyocardial ischemia
and reperfusion. The animals showed an usual high number of
non-lethal arrhythmias (Chong et al., 2014). Compared to small
animalmodels (Laflamme et al., 2007; Shiba et al., 2012), in which
the same human embryonic cells were also used, the high number
of non-lethal arrhythmias seen in the non-primate model may be
explained by graft automaticity. These animals have lower heart
rates compared to the smaller animals (mice and rats) used prior
(Chong et al., 2014).
TRIGGERED ACTIVITY
Triggered activity initiated by (delayed or early) after depolariza-
tions, may also be involved in arrhythmogenesis caused by stem
cell therapy (Figure 1D).
Although a scarce number of studies concerning human
embryonic stem cell derived CM (Jonsson et al., 2011) and
induced pluripotent stem cell derived CM (Knollmann, 2013)
have been performed to look at pro-arrhythmic potential, no
conclusion can be drawn yet to associated stem cells directly with
early after depolarizations or delayed after depolarizations.
SYMPATHETIC HYPER-INNERVATION
Stimulation of sympathetic nerve sprouting is an alternative
mechanism of stem cells that promote arrhythmogenesis (Pak
et al., 2003; Kim et al., 2010). Although this process does not
require the formation of gap junctions it is important to keep
in mind when evaluating the safety of stem cells. The heart is
innervated by both the parasympathetic and sympathetic ner-
vous system (Figure 1E), whereby the latter has a higher density
in de sub-epicardium and central conduction system (Kawano
et al., 2003). Sympathetic stimulation leads to acceleration of
the heart rate, contractility and can improve cardiac output.
However, it has also been shown that disturbed innervation can
cause lethal arrhythmias (Cao et al., 2000). Pak et al. stated that
MSC induce cardiac nerve sprouting in a large animal model
of MI (Pak et al., 2003). One month post MI induction, swines
received injections of either a mixture of MSC and bone marrow
cells, bone marrow cells alone or only the culture medium. One
month later the animals were killed and immunofluorescence
staining was performed on tissue samples. Samples were stained
for nerve sprouting (growth-associated protein; GAP-43), sympa-
thetic nerves (tyrosine hydroxylase; TH) and for tenascin expres-
sion. Animals receiving the combination treatment showed more
GAP43-positive nerves, higher density of sympathetic nerves
and higher tenascin expression (Pak et al., 2003) suggesting an
increase in cardiac (sympathetic) nerve sprouting.
Kim et al. saw similar results when MSCs were injected
in the myocardium of canines. In addition, he demonstrated
the pro-arrhythmic risk of this hyper-innervation (Kim et al.,
2010). Occurrence of ventricular fibrillation was 0% in the sham
group and 33.3% in the group who received MSC. Hyper-
innervation may therefore be an important mechanism for the
pro-arrhythmic potential of stem cells.
PARACRINE FACTORS
An additional mechanism through which stem cells can be pro-
arrhythmic is the influence of secreted paracrine factors or fac-
tors released once these cells are connected to cardiomyocytes
(Figure 1F). Although the “paracrine hypothesis” (Gnecchi et al.,
2008) is suggested to be an indirect mechanism behind improve-
ment in left ventricular (LV) function, changes in scar prop-
erties, angiogenesis induction and/or improvement in survival
of endogenous cardiomyocytes, several studies have documented
pro-arrhythmic effects of paracrine factors (Pedrotty et al., 2009;
Askar et al., 2013). However, the actual factor(s) and mechanism
behind these observed results still need to be identified.
CONCLUSION
After nearly two decades of research in stem cell based therapies
for cardiac regeneration the search for the “perfect” stem cell—
based therapy for cardiac tissue regeneration continues as there
are still many questions left that remain unanswered.
Stem cells have the ability to couple electrically to cardiomy-
ocytes via gap junctions. Formations of functional intercellular
connections influence the electrical properties of cardiomyocytes
and are associated with pro-arrhythmic effects. Depolarization
of resting membrane, heterogeneous conduction slowing, and
electrical instability are factors that can occur after electrotonic
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connections between stem cells and cardiomyocytes are formed.
Depending on themagnitude of effect these factors can contribute
to the formation of arrhythmias.
Future studies should not only be aimed at efficacy and long-
term effects but also inmaking clinical trials similar so that factors
(e.g., different in/exclusion criteria, cells dose/type, timing, and
route of cell infusion) contributing to conflicting data can be lim-
ited and a provide solid framework for the safe application of stem
cells without arrhythmogenic side effects.
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